HC Wainwright Weighs in on Clene’s Q1 Earnings (NASDAQ:CLNN)

Clene Inc. (NASDAQ:CLNN) – Research analysts at HC Wainwright issued their Q1 2025 earnings estimates for Clene in a report released on Monday, March 24th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings per share of ($1.11) for the quarter. HC Wainwright currently has a “Buy” rating and a $31.00 price target on the stock. The consensus estimate for Clene’s current full-year earnings is ($5.19) per share. HC Wainwright also issued estimates for Clene’s Q2 2025 earnings at ($1.15) EPS, Q3 2025 earnings at ($1.28) EPS, Q4 2025 earnings at ($1.35) EPS, FY2025 earnings at ($4.92) EPS, FY2026 earnings at ($3.02) EPS and FY2027 earnings at $0.52 EPS.

Clene (NASDAQ:CLNN) last announced its quarterly earnings results on Monday, March 24th. The company reported ($1.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.46). The company had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.13 million. Clene had a negative net margin of 8,556.77% and a negative return on equity of 1,106.30%.

Separately, D. Boral Capital restated a “buy” rating and issued a $23.00 price objective on shares of Clene in a report on Monday. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $55.25.

Clene Trading Down 10.2 %

Shares of Clene stock opened at $3.18 on Wednesday. The business’s fifty day moving average price is $4.46 and its 200 day moving average price is $4.87. Clene has a twelve month low of $3.09 and a twelve month high of $9.20. The stock has a market capitalization of $26.48 million, a P/E ratio of -0.60 and a beta of 0.27.

Hedge Funds Weigh In On Clene

Hedge funds and other institutional investors have recently made changes to their positions in the business. Parsons Capital Management Inc. RI purchased a new position in Clene in the fourth quarter valued at about $194,000. SBI Securities Co. Ltd. purchased a new stake in shares of Clene during the 4th quarter valued at about $69,000. Fullcircle Wealth LLC acquired a new position in Clene during the 4th quarter worth approximately $69,000. Renaissance Technologies LLC purchased a new position in Clene in the 4th quarter worth approximately $96,000. Finally, Geode Capital Management LLC grew its position in Clene by 52.9% in the fourth quarter. Geode Capital Management LLC now owns 65,112 shares of the company’s stock valued at $346,000 after acquiring an additional 22,539 shares in the last quarter. Institutional investors and hedge funds own 23.28% of the company’s stock.

Clene Company Profile

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.